Last reviewed · How we verify
Gonadotropin-releasing Hormone Analog
GnRH analogs bind to gonadotropin-releasing hormone receptors in the pituitary gland to suppress the release of luteinizing hormone and follicle-stimulating hormone, thereby reducing sex hormone production.
GnRH analogs bind to gonadotropin-releasing hormone receptors in the pituitary gland to suppress the release of luteinizing hormone and follicle-stimulating hormone, thereby reducing sex hormone production. Used for Advanced prostate cancer, Breast cancer (hormone-receptor positive), Endometriosis.
At a glance
| Generic name | Gonadotropin-releasing Hormone Analog |
|---|---|
| Also known as | GnRH Agonist, GnRH Analog, Gonadotropin-Releasing Hormone Agonist, Gonadotropin-Releasing Hormone Analogue, LH-RH agonist |
| Sponsor | Rutgers, The State University of New Jersey |
| Drug class | GnRH agonist |
| Target | GnRH receptor |
| Modality | Biologic |
| Therapeutic area | Oncology; Endocrinology |
| Phase | FDA-approved |
Mechanism of action
GnRH analogs are synthetic peptides that mimic the natural GnRH hormone. Initially, they stimulate the pituitary gland, but with continuous exposure they cause desensitization and downregulation of GnRH receptors, leading to sustained suppression of gonadotropin secretion and consequent reduction in testosterone and estrogen levels. This mechanism is exploited therapeutically in hormone-dependent cancers and certain reproductive disorders.
Approved indications
- Advanced prostate cancer
- Breast cancer (hormone-receptor positive)
- Endometriosis
- Uterine fibroids
- Precocious puberty
Common side effects
- Hot flashes
- Decreased libido
- Erectile dysfunction
- Injection site reactions
- Headache
- Bone density loss (with prolonged use)
- Mood changes/depression
Key clinical trials
- A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss (PHASE2)
- A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer (PHASE1, PHASE2)
- Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma (PHASE2)
- A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma (PHASE2)
- Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP Patients (PHASE2)
- Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires
- Body Composition Assessment in Transgender Population.
- Artificial Cycle With or Without GnRH Agonist Pre-treatment for Frozen Embryo Transfer in Adenomyosis Patients (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |